Ipilimumab is currently under phase 2 clinical trials for metastatic, recurrent, or last-staged NPC.CTLA-4 inhibitors are also under clinical investigation in other cancers, including lung cancer, prostate cancer, and NPC [62]. The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.